Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | IDO1 | P14902 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29838484 | 0.80 | GAA (0.67) | GAAMAPTGLAALDH1A1IDO1 | |
| SCHEMBL526255 | 0.80 | GAA (0.67) | GAAMAPTGLAALDH1A1IDO1 | |
| SCHEMBL667827 | 0.79 | CA2 (0.67) | GAAMAPTGLAALDH1A1LMNA | |
| SCHEMBL7043304 | 0.78 | GAA (0.64) | GAAMAPTGLAALDH1A1IDO1 | |
| SCHEMBL9690067 | 0.76 | GAA (1.00) | GAAMAPTGLAALDH1A1IDO1 | |
| SCHEMBL15541297 | 0.74 | MAPT (0.59) | GAAMAPTGLAALDH1A1IDO1 | |
| SCHEMBL27897553 | 0.74 | GAA (1.00) | GAAMAPTGLAALDH1A1IDO1 | |
| SCHEMBL8231131 | 0.73 | MAPT (0.58) | GAAMAPTGLAALDH1A1IDO1 | |
| SCHEMBL28916359 | 0.73 | CA2 (0.60) | GAAMAPTGLAALDH1A1LMNA | |
| SCHEMBL4555003 | 0.71 | IDO1 (0.78) | GAAMAPTALDH1A1IDO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097394-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2013-12-25 | — | — | EP | disclosed |
| US-8349878-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-01-08 | — | — | US | disclosed |
| CN-101595098-B | 1,2,4-triazole derivatives as sigma receptor inhibitors | ESTEVE LABOR DR | 2012-07-18 | — | — | CN | disclosed |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
| US-8039497-B2 | 1,2,4-triazole derivatives as sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-10-18 | — | — | US | disclosed |
| US-20100004224-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-01-07 | — | — | US | disclosed |
| CN-101595098-A | As 1,2 of sigma receptor inhibitors, the 4-triazole derivative | ESTEVE LABOR DR (ES) | 2009-12-02 | — | — | CN | disclosed |
| EP-2097394-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008055932-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-05-15 | — | — | WO | disclosed |
| EP-1921073-A1 | 1,2,4-Triazole derivatives as sigma receptor inhibitors | Laboratorios del Dr. Esteve S.A. (ES) | 2008-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004224-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | GAA 2370/4885MAPT 2182/4885GLA 4736/4885 |
| US-20120004211-A1 | 1,2,4-TRIAZOLE DERIVATIVES AS SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRK1 | GAA 2286/4885MAPT 2290/4885GLA 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.